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doi:10.1016/j.jtcvs.2006.08.077bjectives: Cell therapy may offer novel therapeutic options for chronic ischemic
eart disease. In a clinical trial, we first assessed the feasibility and safety of
ntramyocardial CD133 bone marrow cell injection together with coronary artery
ypass grafting (CABG). We then tested the hypothesis that CABG plus CD133
ell injection would result in better contractile function than CABG alone.
ethods: Fifteen patients took part in the safety study, followed by 40 patients who
nderwent either CABG with cell therapy or CABG alone. Bone marrow was
arvested from the iliac crest one day before surgery, and purified CD133 pro-
enitor cells were injected in the infarct border zone during the CABG operation.
V function was measured by echocardiography and myocardial perfusion by
PECT.
esults: In the safety study, no procedure-related complications were observed for
p to 3 years. LV injection fraction (LVEF) increased from 39.0%  8.7%
reoperatively to 50.2%  8.5% at 6 months and 47.9%  6.0% at 18 months (F
6.03, P  .012). In the efficacy study, LCEF rose form 37.4%  8.4% to 47.1%
8.3% at 6 months in the group with CABG and cell therapy (F  24.16, P 
0001) but only from 37.9%  10.3% to 41.3%  9.1% in the CABG-only group
F  7.72, P  .012). LVEF was significantly higher at 6 months in the group with
ABG and cell therapy than in the CABG-only group (P  .03). Similarly,
erfusion of the infarcted myocardium improved more in patients treated with
ABG and cell therapy than in those treated with CABG alone.
onclusion: Intramyocardial delivery of purified bone marrow stem cells together
ith CABG surgery is safe and provides beneficial effects, though it remains to be
een whether thewe effects produce a lasting clinical advantage.
ellular therapy for ischemic heart disease has attracted tremendous attention,
especially since initial experimental studies have suggested that somatic
stem cells can regenerate both blood vessels and cardiomyocytes after
yocardial infarction. Recently, the capacity of bone marrow–derived stem cells to
orm new heart muscle cells has been questioned, but clinical pilot trials have been
nitiated nevertheless.E1,E2 In the setting of acute myocardial infarction, several
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ETtudies have shown a functional benefit of intracoronary
nfusion of bone marrow cells relative to the standard treat-
ent alone,E3-E5 but patients with chronic ischemic heart
isease and impaired heart function may require a different
pproach. Our group therefore developed a protocol for
njection of purified CD133 bone marrow stem cells di-
ectly into the diseased myocardium at the time of coronary
rtery bypass grafting (CABG). Because of the encouraging
esults in the first 6 patients,E6 we completed a dose-esca-
ation safety trial and then conducted an efficacy study to
ompare the outcome with that of standard CABG. Results
f both trials are presented here.
atients and Methods
he study was approved by the institutional review board and
thics committee at Rostock University (including the safety and
he efficacy trial as well as all subsequent protocol modifications).
nclusion criteria were as follows: (1) history of myocardial in-
arction at least 14 days previously, (2) indication for bypass
urgery on coronary arteries other than the infarcted vessel, and (3)
istinct area of akinetic left ventricular (LV) myocardium corre-
ponding with the infarct localization. Exclusion criteria were as
ollows: (1) debilitating chronic disease (eg, malignancy or termi-
al renal failure), (2) emergency operation, (3) concomitant valve
urgery, and (4) history of malignant ventricular arrhythmia. To
ccelerate recruitment, the inclusion criteria were slightly modified
efore the onset of the phase II trial. First, patients needing
oncomitant mitral valve repair for regurgitation were included.
econd, in the absence of a distinctly akinetic area of LV myo-
ardium, a globally reduced LV ejection fraction (LVEF) was
ccepted. Once the presence of the main inclusion criteria was
etermined, enrollment was discussed with the patient and in-
ormed consent was obtained. Then the patient was referred for
yocardial perfusion scintigraphy, Holter electrocardiography
ECG), and, lately, cardiac magnetic resonance imaging (MRI). In
he efficacy study, patient allocation to the CABG alone or CABG
lus cellular treatment group was performed as described in Ap-
endix E1. Preoperative patient characteristics were similar be-
ween the groups and are given in Table E1. Enrollment for the
afety trial began in August 2001 and was completed in February
003. The efficacy study began in May 2003 and was terminated
n February 2005. The recruitment history according to the Con-
olidated Standards of Reporting Trials (CONSORT) guidelines, is
Abbreviations and Acronyms
CABG coronary artery bypass grafting
ECG  electrocardiography
LV  left ventricle
LVEF  LV ejection fraction
MRI magnetic resonance imaging
PBS  phosphate-buffered saline solutioniven in Figure 1. p
18 The Journal of Thoracic and Cardiovascular Surgery ● Marcell Preparation
ne day before CABG, with local anesthesia, bone marrow was
spirated from the iliac crest with preheparinized syringes. The
arrow was brought to the hematology clean room lab, and
D133 stem/progenitor cells were isolated by magnetic sep-
ration with ferrite-conjugated antibody (Miltenyi CliniMacs
ystem; Miltenyi Biotec, Bergisch Gladbach, Germany). Flow
ytometry– based quality control measurements were performed
t various steps throughout the procedure. Details are given in
ppendix E2.
urgical Procedure
ll patients were operated on with cardiopulmonary bypass and
ardioplegic arrest. The left thoracic artery was used in most but
ot all cases (depending on the presence of an anterior vessel that
ould be grafted), and saphenous vein grafts or radial artery grafts
ere harvested. When there was mitral regurgitation grade III or
igher according to transesophageal echocardiography on the op-
rating table, the mitral valve was repaired by ring annuloplasty.
ll coronary arteries with relevant stenoses and sufficient diameter
ere grafted, including, if possible, the previously infarcted vessel.
nce the graft–coronary artery anastomoses had been completed,
he infarcted area was visualized, and 10 injections of 0.2 mL of
ell suspension were made into the infarct border zone if this could
e clearly visualized. Otherwise, cells were injected in an area of
yocardium that corresponded to the localization of the perfusion
efect on scintigraphy and disturbed wall motion on echocardiog-
aphy and LV angiography. A swab was used to occlude the
njection channel for several seconds to minimize reflux of cell
uspension. Immediately after the cell injection, the aortic clamp
as removed, and the operation was completed as usual. In CABG
lone patients, no sham injection was performed. After their stay in
he intensive care unit and the intermediate care unit, patients recov-
red on the surgical ward for at least 12 days or were transferred to the
eferring cardiology unit earlier. Standard postoperative medication
ncluded aspirin (100 mg daily), -blockers, statins, and angiotensin-
onverting enzyme inhibitors and was adjusted by the cardiologist
aring for the patient during follow-up as needed.
utcomes and Follow-up
n the safety study, the primary outcome was freedom from death
rom cardiac disease or major cardiac event at 12 months. Sec-
ndary outcomes were ventricular arrhythmia and any class III
r class IV event according to a modified Centers for Disease
ontrol and Prevention classification. In the efficacy trial, the
ollowing null hypothesis was formulated: At 6 postoperative
onths, there would be no difference in average LVEF between
ABG alone and CABG with cell injection. Secondary outcome
arameters were myocardial perfusion in the infarcted area and
he same safety parameters as in the safety study. Before
eferral to a cardiac rehabilitation program at approximately 2
ostoperative weeks, Holter ECG, transthoracic echocardiogra-
hy, and myocardial perfusion scintigraphy were performed.
he next Holter ECG and echocardiogram were recorded at the
nd of the rehabilitation program in the respective institution;
owever, the echocardiography data were not used for quanti-
ative analysis in the study. Echocardiography and myocardial
erfusion scintigraphy were repeated in our institution at 6
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ETostoperative months in the efficacy trial and also after 18
onths in the safety trial.
chocardiography
ardiac transthoracic ultrasonographic studies were performed for
easurement of global LV contractility and dimensions. The
ethod is described in detail in Appendix E3. The studies were
arried out by two experienced echocardiographers (A.D., C.N.)
ho were blinded to the presence and location of the cell injection.
easurements obtained by the two independent echocardio-
raphers were consistent. In a separate set of patients, the echo-
ardiographic data were validated with cardiac MRI, and a close
orrelation of the LVEF measurements was found (Figure E1).
yocardial Perfusion Scans
or myocardial-perfusion, single-photon emission computed to-
ography at rest, 100 MBq thallous chloride Tl 201 was intrave-
ously injected, and scans were done 5 minutes after injection with
3-head gamma camera (Irix; Philips Nederland BV Medical
ystems, Eindhoven, The Netherlands) in combination with a
onuniform attenuation correction. Images were assessed by quan-
itative measurements of the activity in the area at risk, the infarc-
ion zone, which was expressed as the ratio of postoperative to
Figure 1. Consolidated Standards of Reporting Trials
grafting.reoperative activity. C
The Journal of Thoracictatistical Analysis
ontinuous data are presented as mean  SD. For variables not
ormally distributed, medians and ranges are presented (cell iso-
ation data, infarct time, myocardial perfusion data). To compare
reoperative patient characteristics between the groups, the Stu-
ent t test was used for continuous data and the 2 test was used for
ategorical data. Comparisons of changes in functional data, including
VEF, LV end-systolic volume, LV end-diastolic volume, LV end-
ystolic diameter, and LV end-diastolic diameter with time, were done
ith repeated-measures analysis of variance with the Greenhouse–
eisser F test to evaluate treatment and time effects.E7 Variables not
onforming to a normal distribution (myocardial perfusion data) were
ompared with the Mann–Whitney U test. Agreement between
chocardiography-based and cardiac MRI determinations of LVEF
as determined by the Bland-Altman method, and the mean differ-
nce was used to assess bias and 95% confidence intervals (2 SD).E8
n the basis of the results of the safety trial, the efficacy trial required
version 6.0, nQuery Advisor; Statistical Solutions, Saugus, Mass) 20
atients in each group to attain 80% power for detecting a relative
ifference of 10% in average LVEF between the groups, assuming an
% SD (effect size of 1.25,  .05,  0.2). Statistical analysis was
erformed with the SPSS software package (version 14.0; SPSS Inc,
chart of trial history. CABG, coronary artery bypassflowhicago, Ill).
and Cardiovascular Surgery ● Volume 133, Number 3 719
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ETesults
atient- and procedure-related baseline data are given in
able E1, and no significant differences were found be-
ween the two groups. Overall, 80% of the patients were
ale, and the mean age at surgery was 63  5 years. The
nterval between documented myocardial infarction and sur-
ery ranged from 2 weeks to 3.2 years, with a median of 7.9
eeks. All patients had moderate to severe symptoms of
oronary artery disease with reduced exercise capacity and
hest pain, and the indication for surgery was triple- or
ouble-vessel disease with or without left main coronary
rtery stenosis in all but 1 case. In that case, the primary
ndication for surgery was mitral valve incompetence after
xtensive transmural anterior myocardial infarction; the in-
arcted vessel had been revascularized by percutaneous
ransluminal coronary angioplasty and stent placement 5
ears previously. During surgery, 3.5  0.7 bypass–coro-
ary artery anastomoses per patient were constructed, and
he cell injection was performed as described previously.
uring the postoperative intensive care unit stay, most
atients received low-dose inotropic support until the first
ostoperative day, but none had symptoms of low cardiac
utput requiring high-dose inotrope infusion or intra-aortic
alloon counterpulsation. Two patients per group showed
levated creatine kinase levels on postoperative day 1, but
ithout evidence of acute transmural infarction on ECG.
hese patients were not excluded from further analysis.
one Marrow Cell Preparation
etween 91 and 265 mL (median 156 mL) of bone marrow
as harvested by aspiration from the iliac crest. The median
ercentage of CD34 cells in all bone marrow aspirates was
.8% (range 0.26%-1.44%), corresponding to a median
bsolute number of 2.95  107 CD34 cells (range 3.85 
06-1.03 108). After cell selection with AC133/1(CD133)
onoclonal antibody, the median number of CD133selected/
D34 cells was 5.80  106 (range 1.08  106-8.35 
07), with a median purity of 75.8% (range 53.1%-89.6%).
n only 1 patient (aged 40 years) was the final cell dose
igher than 10 106. Median recovery of CD34 cells was
8.3%. Viability of the cell product, as measured by propi-
um iodide exclusion, ranged between 77% and 99% (me-
ian 94%). For details, see Table E2.
afety Trial Results
ll 15 patients included in the dose-escalation safety trial
olerated the operation well and were extubated during the
rst postoperative night. One patient underwent a rethora-
otomy for bleeding from the internal thoracic artery on the
ay of surgery. Two patients had symptoms of respiratory
ract infection that were treated with antibiotics, and another
patients had transient pleural effusions. Otherwise, in-
ospital convalescence was uneventful, and all patients C
20 The Journal of Thoracic and Cardiovascular Surgery ● Marcere referred to a cardiac rehabilitation program during the
hird postoperative week. Follow-up time currently ranges
etween 30 and 50 months, encompassing a total of 625
atient-months. No relevant ventricular arrhythmia was re-
orded at any point by online telemetric monitoring or
olter ECG, and the reported exercise tolerance improved
n all patients. A 75-year-old patient was unavailable for
ollow-up 9 months after surgery. He had cerebrovascular
isease with a history of multiple transient cerebral isch-
mic events but without gross neurologic deficits at the time
f operation. Subsequent investigation revealed that he had
ied of a stroke. No autopsy was performed. All other
atients were alive and well at the time of preparation of the
aper. By the end of the rehabilitation process, all patients
ut 1 were in New York Heart Association functional class
. Recatheterization was not performed, but there was no
vidence of new regional contractile dysfunction indicating
elevant graft dysfunction. The echocardiographic data of
he safety trial patients are depicted in Figure 2. Overall,
verage LVEF increased significantly, from 39.0%  8.7%
reoperatively to 50.2%  8.5% at 6 months and 47.9% 
.0% at 18 months (Greenhouse–Geisser F  6.03, P 
012, repeated-measures analysis of variance). LV end-
ystolic volume declined significantly, from 92.3  35 mL
reoperatively to 65.4  20 mL at discharge (P  .004),
6.2  24 mL at 6 months (P  .008) and 65.8  11 mL
t 18 months (P  .013). LV end-diastolic volume de-
reased, from 144  37 mL preoperatively to 121  23 mL
t 6 months and 127 18 mL at 18 months, but this did not
epresent a significant change with time (F  2.07, P 
18).
Myocardial perfusion in the area of interest was assessed
y thallium single-photon emission computed tomographic
cans. The activity in the area at risk—expressed as the
atio of postoperative to preoperative activity—demon-
trated improved perfusion in the previously nonperfused or
ypoperfused infarction zone in 13 patients. The median
erfusion ratio after CABG with CD133 cell injection
ncreased by 15% to 1.15 at 2 weeks (P  .01, Wilcoxon
igned rank test) and remained stable with a ratio of 1.14 at
 and 18 months (Figure E2). Figure 3 depicts representa-
ive perfusion scans from a patient who received 5  106
D133selected/CD34 cells in the border zone of a posterior
ransmural myocardial infarction, where no bypass graft
ould be placed. At the time of discharge, there was no
elevant improvement, but perfusion of the ischemic tissue
ad virtually returned to normal 6 months later. This sec-
ndary gain in tissue blood supply may have been attribut-
ble to the cell injection.
fficacy Trial Results
total of 43 patients were assigned to undergo eitherABG with cell injection or CABG alone. In 1 patient of
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EThe CABG with cell injection group, the primary bone
arrow aspirate tested positive for bacterial contamination
n microscopy; the final cell product, although sterile, was
ot delivered. Another patient, who had a long history of
iabetes, had deep sternal wound infection in the second
ostoperative week and required repeated wound revision
Figure 2. Echocardiographic data of patients included
data, left ventricular ejection fraction (LVEF) increased
with CD133 cell injection (F  6.03, P  .012, repeate
fraction values were significantly higher than preoper
.05). B, Trend toward sustained reduction in left ve
discharge). Box plots indicate 25th and 75th percen
maximum values of each data set (whiskers). Asterisk
igure 3. Representative single-photon emission computed tomo-
raphic scans of patient in safety trial who underwent bypass
rafting to left anterior descending coronary artery and its
ranches, as well as injection of 5  106 CD133selected/CD34
ells in posterior infarct area. At discharge (second panel), tracer
ctivity in infarct area was still diminished, but at 6 months (thirdanel), perfusion had virtually returned to normal.
The Journal of Thoracicnd open wound healing. He was hospitalized for 4 months
nd refused further follow-up examinations. In the CABG
lone group, 1 patient was retrospectively excluded because
he refused any follow-up examinations after discharge. All
ut 1 patient who remained in the study had an uneventful
ostoperative course. The only early postoperative compli-
ation was a low cardiac output syndrome with acute renal
ailure in 1 patient, requiring medium-dose catecholamine
reatment and temporary hemofiltration. This patient recov-
red completely and was transferred to the ward on postop-
rative day 6. During the follow-up period, no major ad-
erse events (death, myocardial infarction, or cardiac
eintervention) were reported, and all patients were alive
nd well at most recent follow-up. There was no difference
n New York Heart Association functional class between
roups.
The echocardiographic data on LV function are summa-
ized in Table E3, and the data relevant for the primary
utcome parameter, LVEF at 6 months, are depicted in
igure 4. The average LVEF rose, from 37.4%  8.4% to
7.1%  8.3% at 6 months in patients undergoing CABG
ith cell injection (P  .0001) and from 37.9%  10.3% to
1.3%  9.1% in patients undergoing CABG alone (P 
012). As required by the study protocol, direct comparison
f the primary outcome parameter (average LVEF at 6
onths) between the two treatment groups achieved signif-
cance (P  .03), with the 95% confidence interval for the
ean difference in LVEF between 3% and 11%. Within the
ange of probability defined by the statistical power, the null
ypothesis is therefore rejected, indicating that CABG with
ell injection results in significantly better LVEF than does
ABG alone. The average changes in LVEF were 9.7%
fety trial (n  15). A, Relative to preoperative (preop)
ficantly in response to coronary artery bypass grafting
asures analysis of variance). Left ventricular ejection
values at discharge and at 6 and 18 months (all P <
lar end-diastolic volume (P  .06, preoperative vs
(solid box), median (white bar), and minimum and
cates P < .05 versus preoperative data.in sa
signi
d-me
ative
ntricu
tiles
indi8.8% in the CABG with cell injection group and 3.4%
and Cardiovascular Surgery ● Volume 133, Number 3 721
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ET5.5% in the CABG alone group (P  .02). The mean
ifference between groups in the change in LVEF from
reoperative baseline to 6 postoperative months was 6.3%
95% confidence interval for difference 3%-11%). Figure 5
hows that this difference developed late after CABG, dur-
ng the interval between the time of discharge and 6-month
ollow-up.
As determined with single-photon emission computed
omographic imaging, myocardial perfusion in the area of
nterest at 6 months had improved in 4 CABG alone pa-
ients, versus 11 patients who were treated with CABG with
ell injection (P .05, Fisher exact test). The distribution of
he ratio of colorimetric quantification of tracer activity in
he area of interest was determined relative to the preoper-
tive value. Improvement in perfusion at 6 months was
reater in the CABG with cell injection group (median ratio
.02, interquartile range 0.95-1.11) than in the CABG alone
roup (median ratio 0.95, interquartile range 0.91-1.03;
igure E3).
ubgroup Analysis
y univariate analysis within each group and also within the
ombined cohort of all cell-treated patients (safety trial and
fficacy trial), there was no correlation between the func-
ional effect of the operation (defined as change in LVEF)
nd patient age, cell dose, interval between infarct and
urgery, or any other variable except one preprocedural or
eriprocedural variable. The only relevant association indi-
ated a moderate inverse correlation between preoperative
VEF and the gain in LVEF after CABG with cellular
reatment (Pearson r  0.56, P  .001, n  35). That is,
lower LVEF before the operation was associated with a
arger increase in LVEF after CABG with cell injection
Figure 6, A). Indeed, when all patients who underwent
ABG with cellular treatment are grouped according to
reoperative LVEF ( 35% vs 35%), the notion that
atients with a poorer LVEF benefit more is further sup-
orted. Patients with a preoperative LVEF less than 35%
howed a mean increase of 15.3% (95% confidence interval
0.8%-20.4%), significantly greater than the change in
VEF in patients with preoperative LVEF of at least 35%
increase of 7.8%, 95% confidence interval 4.1%-11.5%, F
 5.87, P  .02, 2-way analysis of variance; Figure 6, B).
iscussion
e evaluated the effects of intramyocardial delivery of
D133 bone marrow cells in chronically ischemic hearts
f patients undergoing CABG. In the initial safety trial, no
ell injection-related complications were observed during
p to 4 years follow-up. LV function improved; however,
he safety trial did not allow differentiation between the
ffects of cell injection and CABG. In the subsequent effi-
acy trial, 40 patients were stratified to undergo CABG with t
22 The Journal of Thoracic and Cardiovascular Surgery ● Marcell injection or CABG alone, and we found that global LV
ystolic function at 6 months was moderately but signif-
cantly better in cell-treated patients. It therefore appears
hat concomitant injection of CD133 bone marrow cells
ields a functional benefit in addition to CABG.
Adult stem or progenitor cells derived from blood or
one marrow are readily available for clinical use, although
xperimental evidence regarding their true myocardial re-
eneration capacity remains inconclusiveE1,E9,E10 Neverthe-
ess, numerous small and large animal studies have provided
vidence of functional benefits of bone marrow–derived
tem cells in ischemic myocardium, even in the absence of
uantitatively relevant cardiomyocyte differentiation.E2,E11
linically available CD34 and CD133 bone marrow
tem cells have proved especially effective for improving
lood supply to ischemic tissue.E10 CD133 cells readily
ssume an endothelial cell phenotype in vitroE12 and have
een shown to improve myocardial function in rats.E7 Our
wn preclinical evaluation in mice showed that human
D133 bone marrow cells increase blood vessel count and
educe cardiomyocytes apoptosis in the infarct border
one.E8 Other possible mechanisms include beneficial ef-
ects on extracellular matrix composition.E13 In this context,
ecent research has identified the hibernating myocardium,
hich is to some degree nearly always present in the
hronic infarct border zone, as a particularly responsive
arget of experimental and clinical cardiac cellular
herapy.E14,E15 On the basis of the existing preclinical evi-
ence, we and others have come to the decision that clinical
ilot trials are justified and in fact needed. In 2001, we
nitiated a phase I analogous safety trial with incremental
scalation of the cell dose. We chose to inject bone marrow
ells enriched for CD133 to avoid potential proinflamma-
ory side effects of unmodified mononuclear cell prepara-
ions on direct delivery to the myocardium. Furthermore, we
eemed it important to work with a well characterized,
istinct cell population. Data from the first patients have
een reported before,E6,E16 and the encouraging results
rompted us to complete the safety trial and proceed with an
fficacy study. Even though the observed difference in
VEF at 6 months is modest, we believe it still serves to
rovide proof of principle, namely that direct intramyocar-
ial injection of purified bone marrow stem/progenitor cells
oes have beneficial effects on chronically ischemic human
earts. This notion has recently been corroborated by other
nvestigators. Erbs and colleaguesE14 showed functional
mprovement after intracoronary injection of peripheral
lood-derived progenitor cells in patients with chronic isch-
mia, and Patel and associatesE17 reported on a trial similar
o ours. In the latter study, CD34 bone marrow cells were
mplanted at the time of off-pump CABG and induced a
ignificantly greater improvement of contractile function
han did CABG alone.
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ETA number of reports on other clinical studies have de-
cribed similar advantageous effects of bone marrow mono-
uclear cells injected in the infarct-related coronary artery
f patients early after acute infarctionE3,E5,E18; however,
ther trials have shown little if any clinical effect.E19 Other
han differences in cell type (CD133 vs bone marrow
ononuclear cells), delivery route (intramyocardial vs in-
racoronary), and concomitant procedures (percutaneous
ransluminal coronary angioplasty vs CABG), the most rel-
vant distinction of our approach is patient selection. With
n interval between myocardial infarction and cellular treat-
ent of several months or years, acute ischemia and sub-
equent local inflammatory infiltration have abated, and
yocardial remodeling processes, including scar formation,
re most likely completed. The cellular mechanisms re-
uired to beneficially influence myocardial function may be
ompletely different from those occurring in the face of
ellular therapy in acutely ischemic hearts. In that respect,
ur patient cohort is not homogenous. In some cases, the
nterval between infarct and cellular treatment was a few
eeks; in others, several years. It therefore seems likely
hat the amount of hibernating myocardium varies greatly
mong individual patients, and this confounding factor
ould contribute to the heterogeneity of the functional
reatment response. In future studies, we plan to localize
nd quantify areas of hibernating myocardium before
ellular treatment and use this information for patient
election or retrospective correlation with functional out-
ome data.
In any event, it should be noted that both cellular therapy
urgery (preoperative) and at 6 months’ follow-up (6
ronary artery bypass grafting alone (n  20), average
9.1% (F  7.72, P  .012, repeated-measures analysis
ery bypass grafting with CD133 bone marrow cell
rose from 37.4%  8% to 47.1%  7% (F  14.84, P <
variance revealed significantly greater increase with
relative to coronary artery bypass grafting alone (P Figure 4. Left ventricular ejection fraction (LVEF) before s
months) for individual patients. A, In patients undergoing co
LVEF (horizontal bar) rose from 37.9%  10.3% to 41.3% 
of variance). B, In patients who underwent coronary art
injection (n  20), average left ventricular ejection fraction
.0001, repeated-measures analysis of variance). Analysis of
coronary artery bypass grafting with CD133 cell injection
.02).igure 5. Mean left ventricular ejection fraction (LVEF) for coro-
ary artery bypass grafting (CABG) and coronary artery bypass
rafting with cellular therapy (CABG & cells) groups, indicating
ignificant improvement for both groups between preoperative
aseline and 6 months but with much larger improvement in
atients treated with coronary artery bypass grafting with cells
han with those treated with coronary artery bypass grafting
lone (9.7%  8.8% vs 3.4%  5.5%, respectively). There was no
ignificant mean difference in left ventricular ejection fraction
etween 2 weeks and 6 months in coronary artery bypass grafting
lone group (P  .52), whereas significant increase was seen in
oronary artery bypass grafting with cellular therapy group (F 
4.84, P < .001). Error bars represent SD. Asterisk denotes sig-
ificant group difference at 6 months (mean difference 6.3%, 95%argets (acutely and chronically ischemic myocardium) are
and Cardiovascular Surgery ● Volume 133, Number 3 723
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ETot mutually exclusive or competitive. Even if treatment of
cute myocardial infarction can be further optimized by
apid cellular therapy, there will always be a substantial
umber of patients who are first seen with heart function
lready impaired because of silent ischemic events or failure
f emergency treatment.
imitations
ur study has a number of limitations, which should be
aken into account when interpreting the results. We did not
ave cardiac MRI, the current clinical criterion standard for
nalysis of global and regional LV contractility, available
uring the first years of the trial, and echocardiographic
VEF measurements are expected to be less accurate. The
reater variability of the LVEF data should be reflected in
oth the cellular treatment group and the CABG alone
roup, however, rendering it unlikely that a systematic error
avors either cohort. Moreover, we validated our echocar-
iography protocol by direct comparison with cardiac MRI–
erived LVEF data and found a close correlation between
he techniques. It is also clear that there is a variable degree
f interplay between myocardial revascularization by
ABG and the effects of the cellular treatment. This cannot
e completely avoided in combination therapy studies, even
f one strictly avoids grafting the previously infarcted ves-
el. Another limitation is the heterogeneity of the preoper-
tive LV contractility, with LVEF ranging between 18%
nd 48%. During the course of the trial, we had the impres-
ion that patients with very poor preoperative LV function
Figure 6. Association between preoperative left ventr
ejection fraction at 6-month follow-up. A, Linear regre
preoperative left ventricular ejection fraction and posto
cell-treated patients (safety and efficacy trials comb
ejection fraction (<35% vs >35%). Patients with preop
increase in LVEF by average of 15.4%, whereas patients
7.8% (F  5.87, P  .02, 2-way analysis of variance).enefited more from CABG with cell injection than did b
24 The Journal of Thoracic and Cardiovascular Surgery ● Marchose with better preservation of LV function. In fact, our
ata clearly indicate this to be the case. We will therefore
im at treating only patients with LVEF less than 35% in
uture trials. As discussed previously, we do not know the
mount of hibernating myocardium in our patients, which
ould help explain the variability of the functional response to
ellular treatment. This is illustrated by the finding that most of
he functional improvement occurred during the early postop-
rative period in the phase 1 study arm, whereas the gain in
VEF developed rather late in the safety trial. Finally, our
tudy was underpowered in terms of detecting differences in
V volumes, which needs to be addressed in large-scale trials.
Given that autologous bone marrow stem cells can in-
eed improve the function of chronically ischemic myocar-
ium in addition to the beneficial effects of traditional
evascularization procedures, we believe that there is room
or substantial further improvement. The cell number we
sed is rather small (only 1 of our patients received 80 
06 CD133 cells; all others received between 1.2 and 10
06 cells), and the overnight storage of the cell product may
ave impaired its biologic activity. In a recent study by
sahara and coworkers,E20 there was a clear dose-response
elationship of human CD34 cells in rats, but it is not clear
ow this translates into the clinical setting. Other cell types
ith a greater likelihood for true cardiomyocyte differenti-
tion (mesenchymal stem cell–derived cells) might ulti-
ately prove more efficient. Strategies to precondition cells
efore implantation by pharmacologic, genetic, or physical
eans are also currently under evaluation. For the time
r ejection fraction (LVEF) and gain in left ventricular
indicated trend toward inverse correlation between
tive change in left ventricular ejection fraction. B, All
) grouped according to preoperative left ventricular
ve left ventricular ejection fraction less than 35% had
baseline LVEF greater than 35% had increase by onlyicula
ssion
pera
ined
erati
witheing, however, clinicians have to resort to clinically avail-
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ETble cell products. On that basis, we believe the approach
hat we have chosen to be effective.
iscussion
ichard D. Weisel (Toronto, Canada). I greatly appreciate the
xcellent presentation, and I thank Drs Steinhoff and Stamm for
ending me the manuscript in advance.
This study is important for cardiac surgeons because it echoes
he information I presented last year suggesting that surgeons not
nly need to bypass coronary arteries, fix ventricles, and repair
alves but also need to change the response of the heart to our
nterventions. Surgeons should introduce biologic interventions
henever they perform mechanical interventions. Your study dem-
nstrates that biologic interventions can have profound effects of
he response of the heart to our mechanical interventions. Unfor-
unately, you have not identified the mechanisms responsible for
he benefit, and we therefore may have difficulty integrating this
pproach into our surgical practice.
When we originally implanted cells into the heart, we thought
e were producing new heart cells. Subsequent studies have
etermined that none of the cells implanted into the heart trans-
ifferentiated into new heart cells. The mechanism responsible for
he improved function seen after the implantation of a variety of
ell types has thus not been elucidated. How does cellular trans-
lantation work? We have previously demonstrated that cellular
ransplantation induces angiogenesis and matrix remodeling, as
ell as recruiting endogenous stem cells from the heart and the
one marrow to the heart. If these are the mechanisms responsible
or the improved function, then perhaps we need to augment those
ffects with any surgical interventions on the heart. So my first
uestion for you is as follows: What is the mechanism responsible
or the functional benefit, and should you augment your cells with
enes or proteins to increase the benefit of cellular transplantation?
o you believe that your cells will transdifferentiate into cardio-
yocytes?
I also had some concerns with your study. You had difficulty
ith the randomization. You were unable to complete the study
ccording to your original trial design because of the unavailability
f the room to perform the bone marrow biopsy. I am therefore
oncerned that you may have biased the randomization.
In your article, you report a significant difference between the
wo groups in end-systolic volume. I was concerned that the
ontrol group, the CABG alone group, had larger hearts before the
peration and that this could not be improved with any type of
herapy. Only 6 of your control patients had improvement postop-
ratively and 14 did not, which is not what we would anticipate
fter CABG. In addition, you did not use the Canadian laser in
our control group. The Canadian laser is the insertion of a needle
nto the heart, which previous investigators have demonstrated to
ncrease angiogenesis. The needle injection itself may have im-
roved the functional outcome, and this procedure was only used
n the cell transplant group, not the control group. I suggest that
ou use needle injection in your proposed phase III trial.
Finally, I was concerned about the randomization, because only
additional patients showed an improvement in LVEF in thereatment versus the control groups. The LVEF increased in 8 s
The Journal of Thoracicreated patients and 6 control patients. This difference was small
ut statistically significant. The difficulty you had with random-
zation thus could have influenced the outcomes.
In summary, I think that this is an important study, and it
ertainly will advance the field. Cardiac surgeons should go on to
he next phase to develop a new treatment to restore cardiac
unction in our patients undergoing CABG. We should establish
he mechanisms responsible for the improved function, however,
ut then augment those effects by adding genes or proteins to the
ells implanted into the infarcted myocardium. Biologic interven-
ions may be as important as mechanical treatments to restore our
atients to full activity.
Dr. Steinhoff. Thank you, Dr. Weisel. The introduction of such
method has several phases, and this first phase I and II study of
D133 intramyocardial stem cell transplantation is testing
afety, and biological effects. Of course, the last is a difficult
ption with the diagnostic methods we have available. To unravel
he underlying mechanisms there has to be a high correspondence
etween experimental models and clinical studies. I think it is
ifficult, at present, to exactly understand the sequence of cellular
eactions that lead to cardiac regenerative processes.
We just had the basic science lecture about apoptosis, and
poptosis is also probably an important feature of exchange of
ells necessary for tissue regeneration. So I think the addition of
nti-apoptotic substances such as genes may be important; we have
one research in anti-apoptotic gene transfer with stem cells and
ound a higher therapeutic effect in experimental models. Or
roteins may be added. There are a number of candidate proteins
hat can improve stem cell function in the heart, which may lead
he next clinical introductory phase. However, we have to learn
tep-by-step how stem cells can be used in cardiac therapy, what
herapeutic effects they have, whether they are safe, whether or not
hey have side effects, how we can apply them, and in what disease
ondition.
In our study, we tried to find such a clinical therapeutic window
reating chronic ischemia with intramyocardial injection of autol-
gous CD133 stem cells as an adjunct to a conventional CABG
rocedure. Of course, we are well aware of the weak points of our
ata. As you mentioned, we do not have a sham needle injection in
he control group. We also had to overcome logistic problems in
he prospective randomization of patients considering the bone
arrow stem cell harvest and cell isolation methods. As compared
o controls, however, we have seen in 35 patients treated with stem
ells a consistent improvement in cardiac function—as great as
7% and with a mean of 10%—and I think that is really impres-
ive. The lack of side effects is giving us confidence to go to the
ext clinical phase III study and to extend the experience. There
re, of course, continuing improvements in isolation methods and
onditioning of cells.
With respect to your mention of the control group, I agree that
ham needle injection would be needed, and a next controlled
tudy should include that. Also, a double-blinded study, as here it
s only a single-blinded study, will be necessary to give the hard
ata needed for clinical introduction. Of course, this will take some
ime, but I am positive that we have good prospects for cardiac
tem cell therapy in chronic ischemic heart disease.
and Cardiovascular Surgery ● Volume 133, Number 3 725
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ppendix E1: Patient Stratification
or the efficacy study arm (efficacy study), a randomization plan
as generated with an open-access web-based tool (http://www.
ufts.edu/gdallal/PLAN.HTM) based on 100 subjects and 5 sub-
locks. This plan was followed for the first 12 patients. Because of
he limited availability of the hematology class B procedure room,
ursuing the trial became increasingly more difficult. The stratifi-
ation strategy was therefore modified. Patients who were operated
n during a week when the procedure room was available were
llocated to the treatment group. When the hematology class B
lean room was not available, the patient was put in the CABG
lone group. Availability of the clean room was beyond the control
f the investigators, resulting in the following allocation sequence:
1000011001110010001 01010100101011110111, where 0 repre-
ents CABG alone and 1 represents CABG with cell injection.
ppendix E2
ell Preparation
andling of the bone marrow after aspiration took place in a good
anufacturing practice unit providing a particle-reduced environ-
ent of European good manufacturing practice guidelines level A
n level B. Before further preparation of the bone marrow, cell
amples were drawn for measurement of stem cell number and
iability and for proof of sterility. After density centrifugation,
ells were transferred into a Cobe 2991 cell processor (Gambro
CT, Lakewood, Colo).E21 The cells were washed twice with
hosphate-buffered saline solution (PBS) containing 5% human
erum albumin (HSA). After washing, the cell suspension was
oncentrated to a volume of 85 mL. Then the AC133 reagent
Miltenyi Biotec) was added to the cell processing bag for 30
inutes of incubation. The cell suspension was washed again
wice with PBS with HSA and adjusted to a final volume of 150
L. Samples were drawn again for quantification of stem cell
umber and viability to monitor the performance of the cell label-
ng procedure. CD133 cells were isolated with a CliniMACS
agnetic Cell Separation device (Miltenyi Biotec). The cell prod-
ct was processed according to the standard program for CD133
ell selection with maximum cell numbers of 6  1010 leukocytes
nd 6 108 CD133 target cells. The CliniMACS column yielded
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ETpurified CD133 cell product suspended in approximately 70
L PBS with HSA.E22 Samples were drawn from the transplant
nd the waste fraction for measurement of cell numbers, purity,
nd viability. The sample for proof of sterility was drawn from the
aste fraction. After calculation of the number of viable stem
ells, the CD133-enriched cell suspension was centrifuged for 10
inutes at 200g, resuspended in PBS with HSA, and then adjusted
o a cell concentration according to the Fibonacci dose escalation
cheme used in the safety study protocol. The cells were aliquoted
nto 2-mL vials. In the efficacy trial, all purified cells were con-
entrated to a final volume of 2 mL.
low Cytometry
Samples were drawn from the unmanipulated bone marrow,
fter incubation with anti-CD133 antibody (before CliniMACS
olumn), from the purified CD133 cell product, and from the
aste fraction of the CliniMACS system. To avoid competitive
inding between fluorochrome-conjugated AC133/1 monoclonal
ntibody (CD133) and the ferrite-conjugated AC133/1 antibody
sed for CliniMACS cell selection, stem cell enumeration was
one with a CD34 (clone 8G12) monoclonal antibody
CD133selected/CD34 cells). The clone AC133/2 was not avail-
ble at the time of the safety trial. Later, fluorochrome-conjugated
C133/2 monoclonal antibody was used in addition for determi-
ation the stem cell number in the phase II trial. Cell counting was
one according to the Interdisziplinäre Gruppe für Labor und
urchflusszytometrie and International Society of Hematotherapy
nd Graft Engineering protocol.E23,E24 In all samples derived from
he selection procedure, cell viability was also measured with
ropidium iodide staining and flow cytometry.
ell Products
The results of bone marrow cell preparation are summarized in
able E2. Because the preparation of the transplant of the first
atient in the safety study was done without density centrifugation,
he previously described analyses were performed without this
atient (that cell preparation resulted in a final transplant dose of
nly 1.18  105 CD133selected/CD34 cells with a purity of 3.5%
nd a recovery of only 2%). By the end of the safety study, a
econd CD133 antibody (clone AC133/2), not interfering with the
C133/1 used for cell selection, became available for diagnostic
se. In 9 cell preparations of the efficacy trial, the stem cell number
as calculated on the basis of both CD133 and CD34 cells.
omparison of the cell counts showed a median number of 6.75 
06 CD133selected/CD34, compared with 7.2  106
D133selected/CD133 cells in the final cell product. Median pu-
ities were 77% in the calculation with CD133selected/CD34 cells
nd 80% when CD133selected/CD133 cells were used for calcu-
ation. These results indicate that CD34 and CD133 measurements
re equally valid for monitoring the efficacy of the cell selection
rocedure.
ppendix E3
chocardiography
ardiac transthoracic ultrasonographic studies were performed
ith a Philips SONOS 7500 echocardiography system (Philips o
The Journal of Thoracic aederland) equipped with a 4-MHz vector array transducer and an
TL HDI 5000 echocardiography system equipped with a vector
rray adult cardiac transducer (ATL Ultrasound, Bothell, Wash).
atients were positioned supine left lateral, with the head slightly
levated when the echocardiograms were performed. The standard
pproach included the parasternal long- and short-axis views and
he apical 3-, 4-, and 5-chamber views. In addition to 2-dimen-
ional images and loops, we also acquired color flow mappings,
ulsed and continuous wave Doppler images to assess the function
f the heart valves. Two-dimensional techniques were used to
rovide visual assessment of LV systolic function, both regional
nd global. LVEF was calculated with the Simpson method, which
ivides the LV cavity into multiple slices of known thickness and
iameter by taking multiple short-axis views at different levels
long the LV long axis and then calculates the volume of each slice
area  thickness). Images and loops were recorded on VHS
ideotape or on magneto-optical disk storage devices for later
nalysis. The studies were carried out by two experienced echo-
ardiographers (A.D., C.N.) who were blinded to the presence and
ocation of the cell injection. Measurements obtained by the two
ndependent echocardiographers were consistent.
alidation of Echocardiography by Cardiac MRI
Methods. To determine validity and reproducibility of echo-
ardiography-based LVEF determination, a separate set of patients
n  13) with similarly impaired LV function who were not
ncluded in the study were examined with cardiac MRI, and
chocardiography was performed by the same investigators using
he same protocol described previously. Cardiac MRI was done
ith ECG-gated sequences in a 1.5-T scanner (Avanto; Siemens
G, Munich, Germany). To determine LVEF, LV end-diastolic
nd end-systolic volumes were determined for calculation of
VEF with breath-hold gradient echo sequences (Cine-True Fast
maging With Steady Precession). Sequence parameters were as
ollows: TR 40.05 ms, TE 1.3 ms, flip angle 80° to 65°, matrix 192
156, slice thickness 8 mm, and field of view 34 to 40 cm. The
V was covered by a continuous stack of short-axis slices. An
nd-diastolic, end-expiratory 4-chamber view served as a reference
o plan the short-axis slices. Image analysis was done blinded,
ithout knowledge of the echocardiographic data, with Argus
oftware (Siemens).
Results. In 13 separate patients with ischemic heart disease
nd impaired LV contractility (average LVEF 31%  5%), LVEF
as measured by both echocardiography (LVEFecho) and cardiac
RI (LVEFMRI). There was a significant positive linear correla-
ion between LVEFecho and LVEFMRI (r2  0.84, P  .001),
escribed by the equation y 0.97x 3.7. Bland-Altman analysis
ndicated a mean difference (bias) between MRI and echocardiog-
aphy of 2.8%, with an SD (precision) of 2.1% (95% confidence
nterval of difference 1.5% to 7.1%; Figure E1). Cardiac MRI
easurements of LVEF on average are 2.8% higher than those
btained by echocardiography. The bias was constant across the range
f LVEF, as indicated by a slope not different from 0 (P  .16).
nd Cardiovascular Surgery ● Volume 133, Number 3 725.e2
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ETigure E1. Bland–Altman plot showing relationship between av-
rage left ventricular ejection fraction (LVEF) versus left ventric-
lar ejection fraction difference between magnetic resonance
maging (MRI) and echocardiography and revealing in general
hat echocardiography provides slight linear underestimation of
eft ventricular ejection fraction relative to cardiac magnetic
esonance imaging. Mean difference is 2.8% (solid line), and
ariability of difference is represented as 95% confidence interval
r limits of agreement (2 SD, dashed lines). Bland–Altman plot
evealed significant underestimation of left ventricular ejection
raction with echocardiography relative to magnetic resonance
maging (P < .01, paired t test), although average difference was
onstant through range of left ventricular ejection fraction (slope
ot significantly different from 0, P  .16).m
25.e3 The Journal of Thoracic and Cardiovascular Surgery ● Migure E2. Myocardial perfusion in ischemic myocardium of pa-
ients included in safety study. Activity in cell-treated area of
nterest was quantified by computerized colorimetric analysis
nd expressed asl ratio with respective preoperative (preop)
alue. Overall, there was sustained improvement of perfusion in
arget area (P < .01, Wilcoxon signed rank test). Box plots
ndicate 25th and 75th percentiles (solid box), median (white bar),
nd minimum and maximum values of each data set (whiskers).igure E3. Myocardial perfusion in ischemic myocardium of pa-
ients included in efficacy study before operation (preop), at
ischarge, and at 6 months’ follow-up. Activity in cell-treated
rea of interest was quantified by computerized colorimetric
nalysis and expressed as ratio with respective preoperative
alue. Solid box represents patients undergoing coronary artery
ypass grafting with CD133 cell injection; open box represents
atients undergoing coronary artery bypass grafting alone. Box
lots indicate 25th and 75th percentiles (box), median (bar), and
inimum and maximum values of each data set (whiskers).
arch 2007
TV
A
S
I
N
C
T
H
I
P
P
P
V
C
H
P
w
L
t
Stamm et al Evolving Technology
ETABLE E1. Patient- and procedure-related baseline data
ariable Safety tr
ge (y, mean  SD) 65.2
ex (male/female) 1
nfarct time (wk, median and range) 7 (2
YHA class (No.)
II 2 (1
II-III 9 (6
III 4 (2
oronary artery stenoses (No.)
LMCA 5 (3
LAD 14 (9
CX 13 (8
RCA 15 (1
arget area (No.)
Anterior
Posterior
Apex
olter (No.)
Relevant VES
Atrial fibrillation
ntraoperative
No. of bypasses (mean  SD) 3.7
LITA use (No.) 1
Mitral valve plasty (No.)
Cell dose ( 106 cells) 0
No. of injections 1
ostoperative
Need for inotropes 10 (6
Mechanical ventilation (h, mean  SD) 6.8
ostoperative creatine kinase (IU, median and range) 435 (1
ostoperative creatine kinase isoenzyme MB (IU,
median and range)
26 (1
ES (% of all QRS) 0.004%
-reactive protein (mg/L, median and range) 36 (1
ospital stay (d, mean  SD) 14
reoperative, perioperative, and postoperative baseline data of patients en
ere no relevant differences between groups. CABG, Coronary artery bypas
AD, left anterior descending coronary artery; CX, circumflex coronary arte
horacic artery; NA, not applicable.ial (n  15)
Efficacy trial
CABG with cell injection
(n  20) CABG only (n  20) P value
 9.1 62 10.2 63.5 8.4 .61
5:0 15/5 16/4 .99
.5-12) 9 (2-1200) 7.5 (2-830) .91
.74
3%) 1 (5%) 2 (10%)
0%) 16 (80%) 14 (70%)
7%) 3 (15%) 4 (20%)
3%) 9 (45%) 7 (35%) .75
3%) 18 (90%) 20 (100%) .49
7%) 14 (70%) 17 (85%) .45
00%) 17 (85%) 18 (90%) .99
3 7 7 .93
8 10 11
4 3 2
0 0 0
0 0 0
 0.8 3.3  1.3 3.6  0.8 .38
4 15 20 .03
0 1 1
.6-5 7.5 (1.2-80) NA
0 10 NA
7%) 11 (55%) 12 (60%) .99
 2 5.6  3 6  2 .62
55-3500) 485 (181-3700) 507 (195-1166) .07
1-84) 24 (15-421) 28 (12-43) .24
 0.009% 0.009% 0.02% 0.02% 0.04% .39
1-75) 41 (12-136) 26 (3-113) .16
 2 14  3 12  2 .18
rolled in the safety study and in the efficacy trial (grouped by treatment). There
s grafting; NYHA, New York Heart Association; LMCA, left main coronary artery;
ry; RCA, right coronary artery; VES, ventricular extrasystoles; LITA, left internalThe Journal of Thoracic and Cardiovascular Surgery ● Volume 133, Number 3 725.e4
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ETABLE E2. Results of bone marrow cell preparation
BM
volume
(mL)
% CD34
in BM
Total CD34
in BM
% CD34 af
AC133/1
selection
ll 156 0.8% 2.9  107 75.8%
afety trial 139 0.9% 3.4  107 80.3%
fficacy trial 163 0.7% 2.8  107 73.2%
rocedures with
AC133/2 count
145 0.7% 2.5  107 77.3%
esults of the bone marrow cell preparation. Data are given as median.
arrow relative to all CD45 cells; Total CD34 in BM, total number of CD
f CD34-labeled cells in cell product after CliniMACS isolation of CD1
ntibody-positive labeled cells in CliniMACS cell product; Absolute CD34
ecovery (%), median recovery of CD34 cells; Viability (%), percentage
ABLE E3. Echocardiographic data
ariable Safety trial (n  15
eft ventricular ejection fraction (%)
Preoperative 39.0 8.7
Discharge 46.9 6.8*
6 mo 50.2 8.5*
18 mo 47.9 6.0*
eft ventricular end-diastolic volume (mL)
Preoperative 147.9 38
Discharge 122.7 32
6 mo 126.5 29
18 mo 127.2 18
eft ventricular end-systolic volume (mL)
Preoperative 92.3 35
Discharge 65.4 20
6 mo 66.2 24
18 mo 65.8 11
eft ventricular end-systolic diameter (mm)
Preoperative 39.5 7.2
Discharge 36.4 7.7
6 mo 41.3 8.8
18 mo 39.2 6.2ter % AC133/2
after cell
selection
Absolute
CD34 after
cell selection
Recovery
(%)
Total CD133
after cell
selection
Viability
(%)
NA 5.8  106 18.3% NA 93.4%
NA 5.02  106 19.1% NA 90.6%
NA 5.96  106 18.3% NA 94.3%
79.8 6.75  106 25.6% 7.19  106 93.5%
BM, Bone marrow; % CD34 in BM, percentage of CD34 cells in fresh bone
34 cells in fresh bone marrow; % CD34 after AC133/1 selection, percentage
33 cells; % AC133/2 after cell selection, percentage of AC133/monoclonal
after cell selection, total number of CD34-labeled cells after CD133 selection;)
Efficacy trial
CABG with cell injection (n  20) CABG only (n  20) P value
37.4 8.4 37.9 10.3 .86
39.7 10.6 40.4 10.9 .55
47.1 8.3* 41.3 9.1* .03†
NA NA
153.9 28 153.7 35 .98
145.9 37 157.9 35 .34
142.8 42 149.3 35 .62
NA NA
96.2  20 94 33 .81
89.1  33 92.2 32 .78
77.1  31 88.5 29 .31
NA NA
42.5 6.2 48.1 7.7 .03†
42.3 7.7 46.3 10.8 .31
40.5 7.0 48.3 9.0 .02†
NA NA
eft ventricular end-diastolic diameter (mm)
Preoperative 54.7 3.9 57.1 5.4 58.9 6.3 .35
Discharge 51.1 5.3 53.1 9.6 56.4 9.2 .89
6 mo 52.8 3.6 54.5 6.9 57.0 5.1 .21
18 mo 52.4 3.1 NA NA
chocardiographic data of patients enrolled in safety study and in efficacy trial (grouped by treatment). P values refer to comparison of coronary artery
ypass grafting alone versus coronary artery bypass grafting with cell injection by 2-way repeated measures analysis of variance. Data are given as
ean SD. CABG, Coronary artery bypass grafting; NA, not applicable. *Significant difference compared with preoperative data; †Statistically significant.
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